In COVID-19 clinical update #121, Dr. Griffin discusses age as a risk factor for severe disease, updated vaccine boosters for the fall, pediatric infection and antibody seroprevalence in Arkansas over the first year of the COVID-19 pandemic, all-cause maternal mortality in the United States before and during the pandemic, and the effect of 2-week interruption in methotrexate treatment and how it impacts vaccine immunity.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode * Age as a risk factor for severe disease (NY Times) * Omicron boosters for the fall (NPR) * Pediatric infection and antibody seroprevalence in Arkansas (PIDS) * All-cause US maternal mortality during pandemic (JAMA) * Effect of 2-week interruption in methotrexate treatment (The Lancet) * PAXLOVID patient eligibility screening checklist (FDA) * Remdesivir fact sheet for providers (Veklury) * Bebtelovimab fact sheet for providers (FDA) * PAXLOVID drug interaction checker (IDSA) * Contribute to FIMRC fundraiser at PWB 35:42 * Dr. Griffin’s treatment guide (pdf) * Letters read on TWiV 914 * Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to daniel@microbe.tv